Quick summary
Testagen is a synthetic tetrapeptide (KEDG) bioregulator by Khavinson targeting testicular tissue. It is studied for supporting testosterone biosynthesis via upregulation of steroidogenic enzymes in Leydig cells, though evidence remains preliminary.
Overview
Testagen is a synthetic tetrapeptide bioregulator (Lys-Glu-Asp-Gly, KEDG) developed by Professor Vladimir Khavinson, targeting testicular tissue and the male reproductive axis. It is studied for its ability to support testosterone biosynthesis, Leydig cell function, and hormonal balance in aging men, with proposed applications in age-related male hypogonadism research.
Mechanism of action
Testagen penetrates both cell and nuclear membranes in testicular and hypothalamic-pituitary target tissues, interacting directly with DNA promoter regions of genes involved in steroidogenesis and gonadal function. It is proposed to stimulate Leydig cell activity by upregulating transcription of enzymes in the testosterone biosynthetic pathway (CYP11A1, 3β-HSD, CYP17A1). Testagen influences both the hypothalamic-pituitary-gonadal (HPG) axis controlling testosterone production and the hypothalamic-pituitary-thyroid (HPT) axis governing metabolic hormones. Like other Khavinson bioregulators, its tissue specificity arises from DNA sequence recognition patterns in the target organ. In aging testicular tissue, the peptide is proposed to reverse age-related epigenetic silencing of steroidogenic gene promoters.
Dosing protocols
| Purpose | Route | Dosage | Frequency | Notes |
|---|---|---|---|---|
| male hormonal research | subcutaneous | 0.1–0.5 mg | daily for 10–20 days | Standard Khavinson protocol: 10-day injection cycles, 2–4 times per year. |
| oral research use | oral | 1–2 mg | daily | Some researchers use oral or sublingual routes; bioavailability data not established. |
Dosing information is for educational purposes only. Consult a qualified healthcare professional before using any peptide.
Research summary
Russian research from Khavinson's group demonstrates Testagen's effects on testosterone pathway gene expression in aged testicular tissue models, with animal studies showing improved Leydig cell function and testosterone synthesis. Human evidence is limited to observational data from Russian clinical programs in aging men. The research base does not include randomized placebo-controlled trials meeting Western standards. Evidence of benefit in age-related male hypogonadism remains preliminary; no head-to-head comparisons with testosterone replacement therapy have been published.[1][2][3]
Evidence grading
Each claimed benefit is graded by the strength of available evidence. Grades reflect study quality, not effect size.
Strong = multiple RCTs · Moderate = limited trials or observational · Preliminary = animal or in vitro only · Insufficient = anecdotal or no published data
Side effects
Side effects vary by individual. This is not an exhaustive list. Report unusual symptoms to a healthcare professional.
Common stacks
Peptides commonly paired with Testagen for synergistic effects.
Legal status
Not FDA-approved. Developed and studied in Russia; commercially sold as a cytogen bioregulator supplement. Available in Western markets as a research chemical. Not approved for therapeutic human use outside Russia.
Sourcing & access
Research compound
Testagen is classified as a research compound. Regulatory status varies by jurisdiction. Always verify current legal status and source from vendors providing third-party certificates of analysis (COA).
Frequently asked questions
Testagen is a synthetic tetrapeptide (KEDG) from the Khavinson bioregulator family, targeting testicular tissue. It is studied for supporting testosterone biosynthesis, Leydig cell function, and hormonal balance in aging men.
Testagen penetrates cell and nuclear membranes to interact with DNA promoter regions of steroidogenic genes. It is proposed to stimulate Leydig cells by upregulating enzymes in the testosterone biosynthetic pathway (CYP11A1, 3-beta-HSD, CYP17A1) and influences both the HPG and HPT hormonal axes.
Reported side effects are limited to mild injection site irritation and theoretical hormonal axis effects at high doses. The long-term safety profile is unknown. No Western RCTs or head-to-head comparisons with testosterone replacement therapy have been published.
Russian research shows effects on testosterone pathway gene expression in aged testicular tissue models, with animal studies demonstrating improved Leydig cell function. Human evidence is limited to Russian observational data and does not include randomized placebo-controlled trials meeting Western standards.